

**In the Claims:**

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-76. (Cancelled)

77. (Currently amended) A monomeric single-chain Fv (sFv) molecule, said sFv molecule consisting ~~essentially~~ of :

(a) a first polypeptide domain comprising an ordered arrangement of three complementarity determining regions (CDRs) interposed between framework regions (FRs), said FRs derived from a human immunoglobulin, wherein the first polypeptide domain comprises an amino acid sequence of the general formula FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and;

(b) a second polypeptide domain comprising an ordered arrangement of three CDRs interposed between FRs, said FRs derived from a human immunoglobulin, wherein the second polypeptide domain comprises an amino acid sequence of the general formula FR1'-CDR1'-FR2'-CDR2'-FR3'-CDR3'-FR4', wherein each of CDR1, CDR2, CDR3, CDR1', CDR2' and CDR3' is the sequence of amino acids found at amino acid positions 31-35 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 50-66 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 99-104 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 157-167 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 183-189 of SEQ ID NO:6 and the sequence of amino acids found at amino acid positions 222-230 of SEQ ID NO:6, respectively, and further wherein said first and second polypeptide domains together are capable of forming a binding site for c-erbB-2.

78. (Previously presented) The sFv molecule of claim 77, wherein said first and second polypeptides together are capable of forming a humanized antibody.

79. (Previously presented) The sFv molecule of claim 78, wherein said FR sequences are human immunoglobulin framework region sequences of a human myeloma antibody.

80. (Previously presented) The sFv molecule of claim 77, wherein the first and second polypeptide domains are linked by a polypeptide linker.

81. (Previously presented) The sFv molecule of claim 80, wherein the polypeptide linker comprises at least 10 amino acids.

82. (Previously presented) The sFv molecule of claim 81, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

83. (Previously presented) The sFv molecule of claim 78, wherein the first and second polypeptide domains are linked by a polypeptide linker.

84. (Previously presented) The sFv molecule of claim 83, wherein the polypeptide linker comprises at least 10 amino acids.

85. (Previously presented) The sFv molecule of claim 84, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

86. (Previously presented) The sFv molecule of claim 84, comprising the sequence of amino acids of SEQ ID NO:6.